Visualizing hypothesis tests in survival analysis under anticipated delayed effects
Pharmaceutical Statistics · 2024-11 · 23 (6) · 870-883
DOI: 10.1002/pst.2393 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceutical Statistics, online erschienen am 06.05.2024. Verfasst von José L Jiménez und 3 weiteren Autor:innen. Beteiligte Einrichtung: Novartis Pharma A.G., Basel, Switzerland. Hauptthemen laut MEDLINE: Randomized Controlled Trials as Topic, Proportional Hazards Models. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 44 Literaturangaben.
Abstract (Originalsprache)
What can be considered an appropriate statistical method for the primary analysis of a randomized clinical trial (RCT) with a time‐to‐event endpoint when we anticipate non‐proportional hazards owing to a delayed effect? This question has been the subject of much recent debate. The standard approach is a log‐rank test and/or a Cox proportional hazards model. Alternative methods have been explored in the statistical literature, such as weighted log‐rank tests and tests based on the Restricted Mean Survival Time (RMST). While weighted log‐rank tests can achieve high power compared to the standard log‐rank test, some choices of weights may lead to type‐I error inflation under particular conditions. In addition, they are not linked to a mathematically unambiguous summary measure. Test statistics based on the RMST, on the other hand, allow one to investigate the average difference between two survival curves up to a pre‐specified time point —a mathematically unambiguous summary measure. However, by emphasizing differences prior to , such test statistics may not fully capture the benefit of a new treatment in terms of long‐term survival. In this article, we introduce a graphical approach for direct comparison of weighted log‐rank tests and tests based on the RMST. This new perspective allows a more informed choice of the analysis method, going beyond power and type I error comparison.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Novartis Pharma A.G., Basel, Switzerland.
- Janssen Research & Development L.L.C, High Wycombe, UK.
ORCID-Profile: José L Jiménez, Isobel Barrott, Francesca Gasperoni, Dominic Magirr
Zitieren
APA
Jiménez, J. L., Barrott, I., Gasperoni, F., & Magirr, D. (2024). Visualizing hypothesis tests in survival analysis under anticipated delayed effects. Pharmaceutical Statistics, 23(6), 870-883. https://doi.org/10.1002/pst.2393
Vancouver
Jiménez JL, Barrott I, Gasperoni F, Magirr D. Visualizing hypothesis tests in survival analysis under anticipated delayed effects. Pharmaceutical Statistics. 2024;23(6):870-883. doi:10.1002/pst.2393
BibTeX
@article{Jimnez2024,
author = {Jiménez, José L and Barrott, Isobel and Gasperoni, Francesca and Magirr, Dominic},
title = {Visualizing hypothesis tests in survival analysis under anticipated delayed effects},
journal = {Pharmaceutical Statistics},
year = {2024},
volume = {23},
number = {6},
pages = {870--883},
doi = {10.1002/pst.2393}
}
EUVIMED